keyword
MENU ▼
Read by QxMD icon Read
search

Suboxone

keyword
https://www.readbyqxmd.com/read/28604329/report-on-the-first-government-funded-opioid-substitution-programme-for-heroin-users-in-the-western-cape-province-south-africa
#1
Graeme Michie, Shuaib Hoosain, Muiruri Macharia, Lize Weich
BACKGROUND: Although pharmacological opioid substitution treatment (OST) is a well-established treatment modality for heroin addiction, it is a relatively recent introduction in low- and middle-income countries. OBJECTIVE: To report on a pilot OST programme initiated in 2013 that was the only public-funded programme in South Africa (SA) at the time. Participants were offered standard care only (n=68) or, for the OST group (n=67), standard care plus Suboxone (Reckitt Benckiser), a synthetic partial opioid agonist, in a 12-week clinician-monitored programme...
May 24, 2017: South African Medical Journal, Suid-Afrikaanse Tydskrif Vir Geneeskunde
https://www.readbyqxmd.com/read/28454045/canadian-harm-reduction-policies-a-comparative-content-analysis-of-provincial-and-territorial-documents-2000-2015
#2
REVIEW
T Cameron Wild, Bernie Pauly, Lynne Belle-Isle, Walter Cavalieri, Richard Elliott, Carol Strike, Kenneth Tupper, Andrew Hathaway, Colleen Dell, Donald MacPherson, Caitlin Sinclair, Kamagaju Karekezi, Benjamin Tan, Elaine Hyshka
BACKGROUND: Access to harm reduction interventions among substance users across Canada is highly variable, and largely within the policy jurisdiction of the provinces and territories. This study systematically described variation in policy frameworks guiding harm reduction services among Canadian provinces and territories as part of the first national multimethod case study of harm reduction policy. METHODS: Systematic and purposive searches identified publicly-accessible policy texts guiding planning and organization of one or more of seven targeted harm reduction services: needle distribution, naloxone, supervised injection/consumption, low-threshold opioid substitution (or maintenance) treatment, buprenorphine/naloxone (suboxone), drug checking, and safer inhalation kits...
April 25, 2017: International Journal on Drug Policy
https://www.readbyqxmd.com/read/28426507/peripartum-anesthetic-management-of-the-opioid-tolerant-or-buprenorphine-suboxone-dependent-patient
#3
Aileen Pan, Mark Zakowski
Opioid abuse and dependence continues to rise in both the general population and pregnancy, with opioid overdose deaths having quadrupled in the last 15 years. Illicit drug use in last 30 days of pregnancy was over 4% with almost 0.6% documented maternal opiate use at time of birth. The management of the opioid-tolerant, buprenorphine-dependent or methadone-dependent patient in the peripartum period is reviewed. Options for treatment of opioid dependence, acute pain management, and perioperative multimodal analgesia are discussed...
June 2017: Clinical Obstetrics and Gynecology
https://www.readbyqxmd.com/read/27958381/a-polymorphism-in-the-oprm1-3-untranslated-region-is-associated-with-methadone-efficacy-in-treating-opioid-dependence
#4
R C Crist, G A Doyle, E C Nelson, L Degenhardt, N G Martin, G W Montgomery, A J Saxon, W Ling, W H Berrettini
The μ-opioid receptor (MOR) is the primary target of methadone and buprenorphine. The primary neuronal transcript of the OPRM1 gene, MOR-1, contains a ~13 kb 3' untranslated region with five common haplotypes in European-Americans. We analyzed the effects of these haplotypes on the percentage of opioid positive urine tests in European-Americans (n=582) during a 24-week, randomized, open-label trial of methadone or buprenorphine/naloxone (Suboxone) for the treatment of opioid dependence. A single haplotype, tagged by rs10485058, was significantly associated with patient urinalysis data in the methadone treatment group...
December 13, 2016: Pharmacogenomics Journal
https://www.readbyqxmd.com/read/27888979/corrigendum-to-a-comparison-of-suboxone-and-clonidine-treatment-outcomes-in-opiate-detoxification-archives-of-psychiatric-nursing-26-4-2012-316-323
#5
Anthony Steele, Patricia Cunningham
No abstract text is available yet for this article.
December 2016: Archives of Psychiatric Nursing
https://www.readbyqxmd.com/read/27764078/notes-from-the-field-pediatric-emergency-department-visits-for-buprenorphine-naloxone-ingestion-united-states-2008-2015
#6
Daniel S Budnitz, Maribeth C Lovegrove, Mathew R P Sapiano, Justin Mathew, Scott R Kegler, Andrew I Geller, Christian Hampp
Expanding access to office-based medication-assisted treatment with buprenorphine/naloxone for opioid dependence is a key part of the national strategy to address the opioid abuse epidemic (1). However, as buprenorphine/naloxone prescribing increased, emergency department (ED) visits and hospitalizations for unsupervised ingestions by young children began to increase, with buprenorphine/naloxone ingestions becoming the most common cause of hospitalization for medication ingestions by young children during 2010-2011 (2)...
October 21, 2016: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/27431049/buprenorphine-initiation-and-linkage-to-outpatient-buprenorphine-do-not-reduce-frequency-of-injection-opiate-use-following-hospitalization
#7
Phoebe A Cushman, Jane M Liebschutz, Bradley J Anderson, Merredith R Moreau, Michael D Stein
BACKGROUND: Buprenorphine has established effectiveness for outpatient treatment of opioid use disorder. Our previously published STOP (Suboxone Transition to Opiate Program) trial showed that buprenorphine induction, stabilization, and linkage to outpatient treatment in opioid-dependent inpatients (injection and non-injection drug users) decreased illicit opioid use over 6months. The present study was a planned subgroup analysis of injection opiate users from STOP. OBJECTIVE: To determine if inpatient buprenorphine initiation and linkage to outpatient buprenorphine reduce injection opiate users' frequency of injection opiate use (IOU)...
September 2016: Journal of Substance Abuse Treatment
https://www.readbyqxmd.com/read/27083254/simultaneous-quantification-of-buprenorphine-naloxone-and-phase-i-and-ii-metabolites-in-plasma-and-breastmilk-by-liquid-chromatography-tandem-mass-spectrometry
#8
Madeleine J Swortwood, Karl B Scheidweiler, Allan J Barnes, Lauren M Jansson, Marilyn A Huestis
Opioid abuse during pregnancy is associated with fetal growth restriction, placental abruption, preterm labor, fetal death, and Neonatal Abstinence Syndrome. Current guidelines for medication-assisted opioid addiction treatment during pregnancy are methadone or buprenorphine monotherapy. Buprenorphine/naloxone combination therapy (Suboxone(®)) has not been thoroughly evaluated during pregnancy and insufficient naloxone safety data exist. While methadone- and buprenorphine-treated mothers are encouraged to breastfeed, no studies to date investigated naloxone concentrations during breastfeeding following Suboxone administration...
May 13, 2016: Journal of Chromatography. A
https://www.readbyqxmd.com/read/26948856/buprenorphine%C3%A2-%C3%A2-naloxone-plus-naltrexone-for-the-treatment-of-cocaine-dependence-the-cocaine-use-reduction-with-buprenorphine-curb-study
#9
Walter Ling, Maureen P Hillhouse, Andrew J Saxon, Larissa J Mooney, Christie M Thomas, Alfonso Ang, Abigail G Matthews, Albert Hasson, Jeffrey Annon, Steve Sparenborg, David S Liu, Jennifer McCormack, Sarah Church, William Swafford, Karen Drexler, Carolyn Schuman, Stephen Ross, Katharina Wiest, P Todd Korthuis, William Lawson, Gregory S Brigham, Patricia C Knox, Michael Dawes, John Rotrosen
AIMS: To examine the safety and effectiveness of buprenorphine + naloxone sublingual tablets (BUP, as Suboxone(®) ) provided after administration of extended-release injectable naltrexone (XR-NTX, as Vivitrol(®) ) to reduce cocaine use in participants who met DSM-IV criteria for cocaine dependence and past or current opioid dependence or abuse. METHODS: This multi-centered, double-blind, placebo-controlled study, conducted under the auspices of the National Drug Abuse Treatment Clinical Trials Network, randomly assigned 302 participants at sites in California, Oregon, Washington, Colorado, Texas, Georgia, Ohio, New York and Washington DC, USA to one of three conditions provided with XR-NTX: 4 mg/day BUP (BUP4, n = 100), 16 mg/day BUP (BUP16, n = 100, or no buprenorphine (placebo; PLB, n = 102)...
August 2016: Addiction
https://www.readbyqxmd.com/read/26811236/use-of-an-acetyl-derivative-to-improve-gc-ms-determination-of-norbuprenorphine-in-the-presence-of-high-concentrations-of-buprenorphine-in-urine
#10
Joel R Gervais, Gregory A Hobbs
Certain patients being treated with Suboxone™ or Subutex™ can exhibit very high buprenorphine and low norbuprenorphine concentrations in urine. Very high buprenorphine can interfere with buprenorphine-D4 used as an internal standard, causing errors in norbuprenorphine determination by gas chromatography-mass spectrometry (GC-MS). We used a modified method of Wu et al. to introduce norbuprenorphine-D3 as a separate internal standard for norbuprenorphine. This allowed us to accurately measure norbuprenorphine in neat urine specimens when buprenorphine is present in extremely high concentrations...
April 2016: Journal of Analytical Toxicology
https://www.readbyqxmd.com/read/26660174/quantitation-of-total-buprenorphine-and-norbuprenorphine-in-meconium-by-lc-ms-ms
#11
Stephanie J Marin, Gwendolyn A McMillin
Buprenorphine (Suboxone, Zubsolv, Buprenex, Butrans, etc.) is an opioid drug that has been used to treat opioid dependence on an outpatient basis, and is also prescribed for managing moderate to severe pain. Pregnant women may be prescribed buprenorphine as part of a treatment plan for opioid addiction. This chapter quantitates buprenorphine and norbuprenorphine in meconium by liquid chromatography tandem mass spectrometry (LC-MS/MS).
2016: Methods in Molecular Biology
https://www.readbyqxmd.com/read/26437312/management-of-opioid-dependent-patients-comparison-of-the-cost-associated-with-use-of-buprenorphine-naloxone-or-methadone-and-their-interactions-with-concomitant-treatments-for-infectious-or-psychiatric-comorbidities
#12
Carlos Roncero, Raquel Domínguez-Hernández, Tomás Díaz, José Manuel Fernández, Rafael Forcada, José Manuel Martínez, Pedro Seijo, Antonio Terán, Itziar Oyagüez
The objective was to estimate the annual interaction management cost of agonist opioid treatment (AOT) for opioid-dependent (OD) patients with buprenorphine-naloxone (Suboxone®) (B/N) or methadone associated with concomitant treatments for infectious (HIV) or psychiatric comorbidities. A costs analysis model was developed to calculate the associated cost of AOT and interaction management. The AOT cost included pharmaceutical costs, drug preparation, distribution and dispensing, based on intake regimen (healthcare center or take-home) and type and frequency of dispensing (healthcare center or pharmacy), and medical visits...
September 15, 2015: Adicciones
https://www.readbyqxmd.com/read/25823632/trends-in-the-use-of-buprenorphine-by-office-based-physicians-in-the-united-states-2003-2013
#13
Lydia Turner, Stefan P Kruszewski, G Caleb Alexander
BACKGROUND AND OBJECTIVES: Despite buprenorphine's promise as a novel therapy for opioid dependence, little is known about its clinical adoption. We characterized trends in ambulatory use of buprenorphine in the United States. METHODS: Cross-sectional, descriptive analyses of buprenorphine utilization from 2003 to 2013 using the IMS Health National Disease and Therapeutic Index, a nationally representative audit of ambulatory care. The primary unit of analysis was an office visit where buprenorphine was used for opioid dependence (treatment visit)...
January 2015: American Journal on Addictions
https://www.readbyqxmd.com/read/25811238/recognizing-potential-buprenorphine-medication-misuse-product-packaging-does-not-degrade-with-laundering
#14
Erik W Gunderson
BACKGROUND: Expanded office-based buprenorphine opioid dependence treatment is associated with medication misuse and diversion consequences. Recurrent early refill requests may indicate misuse or diversion, although further research is needed on how to effectively recognize and address the issue in clinical practice. In the current study, patient report of damaged medication from laundering prompted evaluation of laundering on degradation of buprenorphine-containing product packages and contents...
2015: Substance Abuse
https://www.readbyqxmd.com/read/25664200/buprenorphine-response-as-a-function-of-neurogenetic-polymorphic-antecedents-can-dopamine-genes-affect-clinical-outcomes-in-reward-deficiency-syndrome-rds
#15
Kenneth Blum, Marlene Oscar-Berman, William Jacobs, Thomas McLaughlin, Mark S Gold
There is a plethora of research indicating the successful treatment of opioid dependence with either buprenorphine alone or in combination with naloxone (Suboxone®). However, we encourage caution in long-term maintenance with these drugs, albeit, lack of any other FDA approved opioid maintenance compound to date. Our concern has been supported by severe withdrawal (even with tapering of the dosage of for example Suboxone® which is 40 times more potent than morphine) from low dose of buprenorphine (alone or with naloxone)...
2014: Journal of Addiction Research & Therapy
https://www.readbyqxmd.com/read/25663675/determination-of-buprenorphine-norbuprenorphine-and-naloxone-in-fingernail-clippings-and-urine-of-patients-under-opioid-substitution-therapy
#16
Manolis N Tzatzarakis, Elena Vakonaki, Leda Kovatsi, Stamatis Belivanis, Mary Mantsi, Athanasios Alegakis, Jyrki Liesivuori, Aristidis M Tsatsakis
The aim of this study was to develop and validate a method for the determination of buprenorphine (BUP), norbuprenorphine (NBUP) and naloxone (NAL) in fingernails and urine samples collected from former heroin users under suboxone substitution therapy. The analytes were extracted by solid-liquid or solid-phase extraction and were analyzed by liquid chromatography-mass spectrometry. The validation of the analytical methods developed included linearity, recovery, accuracy, precision, ion suppression, sensitivity of interfaces and limits of determination and quantification...
May 2015: Journal of Analytical Toxicology
https://www.readbyqxmd.com/read/25603822/pharmacokinetics-of-sublingual-buprenorphine-and-naloxone-in-subjects-with-mild-to-severe-hepatic-impairment-child-pugh-classes-a-b-and-c-in-hepatitis-c-virus-seropositive-subjects-and-in-healthy-volunteers
#17
MULTICENTER STUDY
Azmi F Nasser, Christian Heidbreder, Yongzhen Liu, Paul J Fudala
BACKGROUND AND OBJECTIVES: Suboxone(®) is a sublingual tablet of buprenorphine/naloxone, approved for the treatment of opioid dependence. The objective of this study was to quantify the impact of hepatic impairment or hepatitis C virus infection on the pharmacokinetics of buprenorphine or naloxone and their major metabolites. METHODS: Forty-three subjects received a single dose of a Suboxone 2.0/0.5-mg tablet. Blood samples were collected up to 168 h and pharmacokinetic parameters were calculated using non-compartmental analysis...
August 2015: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/25456093/opioid-addicted-buprenorphine-injectors-drug-use-during-and-after-12-weeks-of-buprenorphine-naloxone-or-methadone-in-the-republic-of-georgia
#18
RANDOMIZED CONTROLLED TRIAL
Gvantsa Piralishvili, David Otiashvili, Zura Sikharulidze, George Kamkamidze, Sabrina Poole, George E Woody
AIMS: The aim of this study is to assess the prevalence of non-opioid drug use among opioid-addicted, buprenorphine injecting individuals in Georgia, during and after a 12-week course of buprenorphine-naloxone (Suboxone®) or methadone. METHODS: Randomized controlled trial with daily observed Suboxone® or methadone and weekly counseling, urine tests and timeline followback (TLFB) in weeks 0-12 and 20, and the Addiction Severity Index (ASI) at weeks 0, 4, 8, 12, 20...
March 2015: Journal of Substance Abuse Treatment
https://www.readbyqxmd.com/read/25409987/trends-in-the-use-of-buprenorphine-by-office-based-physicians-in-the-united-states-2003-2013
#19
Lydia Turner, Stefan P Kruszewski, G Caleb Alexander
BACKGROUND AND OBJECTIVES: Despite buprenorphine's promise as a novel therapy for opioid dependence, little is known about its clinical adoption. We characterized trends in ambulatory use of buprenorphine in the United States. METHODS: Cross-sectional, descriptive analyses of buprenorphine utilization from 2003 to 2013 using the IMS Health National Disease and Therapeutic Index, a nationally representative audit of ambulatory care. The primary unit of analysis was an office visit where buprenorphine was used for opioid dependence (treatment visit)...
November 19, 2014: American Journal on Addictions
https://www.readbyqxmd.com/read/25334346/revisiting-alveolar-hypoventilation-effect-of-methadone-on-ventilation-in-a-patient-with-chronic-obstructive-pulmonary-disease
#20
Benjamin Wu, Shawn Cohen, Natoushka Trenard, Gregory Mints, Roberta Goldring, Kenneth Berger
Miscellaneous Case Report Posters ISESSION TYPE: Affiliate Case Report PosterPRESENTED ON: Tuesday, October 28, 2014 at 01:30 PM - 02:30 PMINTRODUCTION: A case report of a patient with severe lung disease on methadone with chronic hypercapnia. Specific mechanism for chronic hypercapnia is explored with spirometry, ventilation awake and asleep, and CO2 response.CASE PRESENTATION: A 68 year old man with a history of hypertension, tobacco use, methadone maintenance, presented with chronic hypercapnia (pH 7.43, PCO2 55mmHg, CO2 30 mmol/L)...
October 1, 2014: Chest
keyword
keyword
328
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"